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Abstract A patient known to have renal insufficiency was
admitted to the hospital with fever and pancytopenia after
returning from a trip to Mali. Pancytopenia was not caused
by a tropical infection but was a side effect of atovaquone/
proguanil used as malaria chemoprophylaxis. High and
prolonged detectable proguanil serum levels can result in
bone marrow suppression in patients with renal insufficien-
cy. This should be taken into account in a returning traveller
with fever and pancytopenia.
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To the Editor,
An increasing number of people with chronic diseases
travel to malaria endemic areas. Atovaquone/proguanil
(Malarone) 250/100 mg is being used as one of the first
choice agents for malaria chemoprophylaxis but is contra-
indicated in people with glomerular filtration rate (GFR)
<30 ml/min.
We saw a 49-year old woman with diarrhoea, fever and
pancytopenia after a 2-week trip to Mali. She was known to
have hypertrophic cardiomyopathy and chronic renal
insufficiency (estimated GFR 36–50 ml min
−1 1.73 m
−2)
for which she used carvedilol, lisinopril and furosemide.
She developed abdominal cramps, watery diarrhoea and
fever 1 week after arrival in Mali. The symptoms arose
2 days after drinking water from a well. Four days after
returning from Mali she presented in the emergency room
with persisting diarrhoea, nausea and fever (38.5°C). She
was still taking atovaquone/proguanil as malaria prophy-
laxis. On admittance we saw a dehydrated, non-acutely ill-
appearing patient with pulse rate 70/min, blood pressure
120/70 mm Hg and a temperature of 38.3°C. Besides right
lower quadrant tenderness, physical examination was
unremarkable. Laboratory results revealed a pancytopenia
(Hb 5.7 mmol/l, MCV 90, leucocytes 2.5×10
9/l, thrombo-
cytes 80×10
9/l). There were no signs of diffuse intravas-
cular coagulation. No previous results of blood counts were
available. Serum creatinin was 279 μmol/l (eGFR 17 ml
min
−1 1.73 m
−2).
The clinical diagnosis was gastroenteritis but leptospi-
rosis, malaria, dengue and typhoid fever were also
considered because of pancytopenia. Malaria thick smear
and blood cultures were negative. She was rehydrated,
and 2 days later she was treated with clarithromycin
according to the fecal culture that grew Campylobacter
jejuni. She recovered slowly, and after 2 weeks her
hemoglobin level gradually increased to 8.9 mmol/l,
leucocytes to 5.6×10
9/l and thrombocytes to 150×10
9/l.
By exclusion, pancytopenia was ascribed to proguanil
toxicity, likely because of deteriorated renal function by
dehydration due to gastroenteritis. Afterwards, serum
levels of proguanil were measured. The results are
outlined in Fig. 1. The calculated half-life of proguanil
w a so v e r2 6hb e i n gt w i c ea sl o n ga si nh e a l t h ys u b j e c t s
[1]. In addition, the CYP2C19 enzyme was genotyped as
this is known to be involved in proguanil metabolism. The
patient is heterozygotic for the defect *2 allele of
CYP2C19, which is associated with a mildly decreased
metabolic capacity. This may have partly contributed to
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but not its toxicity [2].
Proguanil and its metabolite cycloguanil reduce the
activity of the enzyme dihydrofolate reductase. This
prevents the development of schizonts and inhibits the
primary and secondary exo-erythrocytary forms of ma-
laria [3]. In humans, the enzyme dihydrofolate reductase
catalyzes the reduction of folic acid to dihydrofolate and
tetrahydrofolate [4]. In healthy persons, proguanil levels
are negligible for causing bone marrow suppression but
sufficient for antimalarial activity as proguanil’s affinity
for the plasmodial enzyme is over 100 times greater than
for the human enzyme [5]. However, high and prolonged
detectable serum levels of proguanil and cycloguanil can
also reduce the activity of the human enzyme causing
depletion of intracellular tetrahydrofolate leading to
anemia, leucopenia and thrombocytopenia. Proguanil is
mainly metabolized by CYP2C19 to cycloguanil and 4-
chlorophenylbiguanide [1, 5]. Both proguanil and cyclo-
guanil are excreted by the kidneys and renal insufficiency
is thus associated with proguanil toxicity [3]. Therefore
atovaquone/proguanil is contraindicated in patients with a
glomerular filtration rate <30 ml/min [3].
The development of pancytopenia due to proguanil is
rare. However, pancytopenia in a returning traveller with
fever will usually be ascribed to the cause of the febrile
illness and thus the possibility of proguanil toxicity might
be overlooked. With increasing numbers of travellers with
coexisting conditions, such as renal insufficiency, going to
malaria endemic areas, hematologic side-effects of progua-
nil might arise more frequently.
Based on this case history, we recommend such chemo-
prophylaxis should be discontinued once a traveller presents
with pancytopenia. In addition, this case highlights the
importance of pre-travel counselling in subjects with renal
insufficiency especially once travellers’ diarrhoea occurs.
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Fig. 1 Elimination curve of
proguanil levels in the patient
compared to elimination curve
of healthy subjects [1]. Exten-
sive metabolizers have normal
metabolic capacity of
CYP2C19, a key enzyme in-
volved in the metabolization of
proguanil to cycloguanil. Poor
metabolizers have decreased
metabolic capacity of
CYP2C19. The expected elimi-
nation curve of the patient
would be between the curves of
poor and extensive metabolizers,
but because of impaired excre-
tion due to renal insufficiency
the elimination curve is shifted
to the right. T=0: time of last
tablet of atovaquone/proguanil
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